Brokerages expect K2M Group Holdings, Inc. (NASDAQ:KTWO) to report sales of $66.90 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for K2M Group Holdings’ earnings. K2M Group Holdings reported sales of $59.31 million in the same quarter last year, which suggests a positive year over year growth rate of 12.8%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 1st.

On average, analysts expect that K2M Group Holdings will report full-year sales of $66.90 million for the current year, with estimates ranging from $265.40 million to $267.40 million. For the next fiscal year, analysts forecast that the business will post sales of $302.65 million per share, with estimates ranging from $301.00 million to $304.60 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow K2M Group Holdings.

K2M Group Holdings (NASDAQ:KTWO) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01. K2M Group Holdings had a negative return on equity of 15.45% and a negative net margin of 16.21%. The business had revenue of $65.70 million during the quarter, compared to the consensus estimate of $66.26 million. During the same period in the prior year, the company earned ($0.27) EPS. K2M Group Holdings’s revenue for the quarter was up 11.0% on a year-over-year basis.

KTWO has been the subject of several recent analyst reports. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of K2M Group Holdings in a research report on Thursday, June 22nd. Royal Bank Of Canada restated a “buy” rating and set a $26.00 target price on shares of K2M Group Holdings in a research report on Thursday, July 20th. BidaskClub upgraded K2M Group Holdings from a “hold” rating to a “buy” rating in a research report on Wednesday, July 19th. Cowen and Company restated a “buy” rating and set a $26.00 target price on shares of K2M Group Holdings in a research report on Wednesday, July 19th. Finally, Needham & Company LLC restated a “buy” rating on shares of K2M Group Holdings in a research report on Wednesday, August 2nd. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $27.14.

Shares of K2M Group Holdings (NASDAQ KTWO) traded up 1.331% during mid-day trading on Monday, hitting $20.935. The company had a trading volume of 98,191 shares. The company’s 50-day moving average is $23.15 and its 200 day moving average is $22.35. K2M Group Holdings has a one year low of $16.32 and a one year high of $25.99. The company’s market capitalization is $905.82 million.

In other news, CFO Gregory S. Cole sold 39,357 shares of the company’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $23.37, for a total value of $919,773.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Philip Md Kostuik sold 1,090 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $24.08, for a total value of $26,247.20. Following the completion of the transaction, the insider now owns 201,961 shares of the company’s stock, valued at $4,863,220.88. The disclosure for this sale can be found here. Insiders sold a total of 45,085 shares of company stock valued at $1,056,903 over the last quarter. Company insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. 1st Global Advisors Inc. boosted its holdings in shares of K2M Group Holdings by 2.9% in the 1st quarter. 1st Global Advisors Inc. now owns 13,101 shares of the medical device company’s stock worth $269,000 after purchasing an additional 369 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of K2M Group Holdings by 9.1% in the 1st quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock worth $138,000 after purchasing an additional 564 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of K2M Group Holdings by 0.3% in the 2nd quarter. Macquarie Group Ltd. now owns 200,656 shares of the medical device company’s stock worth $4,888,000 after purchasing an additional 581 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of K2M Group Holdings by 0.9% in the 2nd quarter. Wells Fargo & Company MN now owns 63,322 shares of the medical device company’s stock worth $1,542,000 after purchasing an additional 590 shares in the last quarter. Finally, American International Group Inc. boosted its holdings in shares of K2M Group Holdings by 7.1% in the 1st quarter. American International Group Inc. now owns 15,847 shares of the medical device company’s stock worth $325,000 after purchasing an additional 1,047 shares in the last quarter. Hedge funds and other institutional investors own 97.86% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/18/brokerages-expect-k2m-group-holdings-inc-ktwo-will-post-quarterly-sales-of-66-90-million.html.

K2M Group Holdings Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group Holdings (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.